Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trifarotene - Galderma/Mayne Pharma

Next Previous
Drug Profile

Trifarotene - Galderma/Mayne Pharma

Alternative Names: AKLIEF; CD-5789

Latest Information Update: 05 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galderma
  • Developer Galderma; Mayne Pharma Group
  • Class Antiacnes; Antineoplastics; Benzoic acids; Keratolytics; Pyrrolidines; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ichthyosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acne vulgaris
  • Phase II Ichthyosis
  • No development reported Cutaneous T-cell lymphoma

Most Recent Events

  • 05 Dec 2025 Launched for Acne vulgaris (In children, In adolescents, In adults) in Australia (Topical)
  • 23 Sep 2025 Phase-III clinical trials in Acne vulgaris (In children, In adults, In the elderly, In adolescents) in China (Topical) (NCT07186413)
  • 22 Sep 2025 Galderma plans a phase III AKLIEF trial for Acne vulgaris (In children, In adolescents, In adults, In the elederly) (Topical) (NCT07186413)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top